Ticker brief
NWBO NORTHWEST BIOTHERAPEUTICS
Consumer, Non-cyclical · Pharmaceuticals
last close
$0.1517
1 day
+0.5%
14 days
-3.4%
mkt cap
$312.2M
signals 14d
18
authors 14d
5
crowd 14d
+1.6σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-16 · now +0.40 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @YYDSxjm | B | -0.25 | 8 | +0.75 |
| @PK_Fund | C | -0.52 | 7 | +0.73 |
| @biggercapital | C | · | 1 | +0.45 |
| @Tickeron | C | +1.53 | 1 | +0.40 |
| @ChrisLaCoursie1 | C | -1.99 | 1 | +0.10 |
Recent signals18of 18 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @ChrisLaCoursie1 | +0.10 | Expresses excitement that an upcoming MONI conference call could benefit retail holders. | -3.1% | tweet ↗ |
| 2026-10-16 | @YYDSxjm | +0.80 | Calls NWBO extremely undervalued while citing encouraging early immunotherapy data. | -3.1% | tweet ↗ |
| 2026-10-16 | @PK_Fund | +0.30 | Cites a breast-cancer trial testing dendritic-cell immunotherapy as a chemotherapy replacement. | -3.1% | tweet ↗ |
| 2026-10-14 | @PK_Fund | +0.75 | Calls newly released UK government information huge, but the linked substance is unavailable. | -5.2% | tweet ↗ |
| 2026-10-14 | @YYDSxjm | +0.70 | Describes NWBO's announced Phase 2 collaboration as evidence of platform expansion and strategic growth. | -5.2% | tweet ↗ |
| 2026-10-14 | @YYDSxjm | +0.85 | Strongly expects broad approval and further international or pharmaceutical partnerships. | -5.2% | tweet ↗ |
| 2026-10-14 | @PK_Fund | +0.75 | Bullish thesis attributes heavy volume and weak price to short suppression ahead of possible approval. | -5.2% | tweet ↗ |
| 2026-10-13 | @YYDSxjm | +0.80 | Highlights accelerating volume, bullish indicators and possible broader patient access. | -6.6% | tweet ↗ |
| 2026-10-13 | @PK_Fund | +0.80 | Calls NHS news highly positive and argues heavy volume may reflect buying despite suspected suppression. | -6.6% | tweet ↗ |
| 2026-10-12 | @Tickeron | +0.40 | First Berlin Equity Research has a $1 target on NWBO tied to UK approval and a 2027 launch. | -6.4% | tweet ↗ |
| 2026-10-12 | @YYDSxjm | +0.50 | Uses celebratory language to endorse DCVax and NWBO. | -6.4% | tweet ↗ |
| 2026-10-08 | @PK_Fund | +0.85 | Interprets UK production support and site expansion as evidence that DCVax-L approval is near. | +2.5% | tweet ↗ |
| 2026-10-08 | @YYDSxjm | +0.90 | Expresses high conviction that NWBO is near MHRA approval based on NHSBT precedents. | +2.5% | tweet ↗ |
| 2026-10-08 | @biggercapital | +0.45 | Suggests official use of the word treatment may be meaningful for NWBO. | +2.5% | tweet ↗ |
| 2026-10-07 | @PK_Fund | +0.80 | Author expects approval and publicity to drive NWBO higher and possibly trigger a squeeze. | +2.2% | tweet ↗ |
| 2026-10-07 | @PK_Fund | +0.85 | Author views an NHS keynote invitation as strong evidence that NWBO approval is imminent. | +2.2% | tweet ↗ |
| 2026-10-07 | @YYDSxjm | +0.80 | Argues clinician interest is creating accelerating momentum for DCVax and urges holders not to exit. | +2.2% | tweet ↗ |
| 2026-10-06 | @YYDSxjm | +0.65 | Reaffirms commitment to NWBO despite frustration with regulators and industry interests. | +3.9% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.